Literature DB >> 27904820

The neurobiology of the Prader-Willi phenotype of fragile X syndrome.

Zukhrofi Muzar1, Reymundo Lozano2, Alexander Kolevzon2, Randi J Hagerman2.   

Abstract

Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and autism, caused by a CGG expansion to greater than 200 repeats in the promoter region of FMR1 on the bottom of the X chromosome. A subgroup of individuals with FXS experience hyperphagia, lack of satiation after meals and severe obesity, this subgroup is referred to have the Prader-Willi phenotype of FXS. Prader-Willi syndrome is one of the most common genetic severe obesity disorders known and it is caused by the lack of the paternal 15q11-13 region. Affected individuals suffer from hyperphagia, lack of satiation, intellectual disability, and behavioral problems. Children with fragile X syndrome Prader-Willi phenotye and those with Prader Willi syndrome have clinical and molecular similarities reviewed here which will impact new treatment options for both disorders.

Entities:  

Keywords:  Autism; FMR1 gene; Fragile X syndrome (FXS); Growth hormone; Hyperphagia; IGF-1; Prader-Willi phenotype

Year:  2016        PMID: 27904820      PMCID: PMC5116860          DOI: 10.5582/irdr.2016.01082

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  66 in total

1.  Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial.

Authors:  Elizabeth M Berry-Kravis; David Hessl; Barbara Rathmell; Peter Zarevics; Maryann Cherubini; Karen Walton-Bowen; Yi Mu; Danh V Nguyen; Joseph Gonzalez-Heydrich; Paul P Wang; Randall L Carpenter; Mark F Bear; Randi J Hagerman
Journal:  Sci Transl Med       Date:  2012-09-19       Impact factor: 17.956

2.  Paternal deletion from Snrpn to Ube3a in the mouse causes hypotonia, growth retardation and partial lethality and provides evidence for a gene contributing to Prader-Willi syndrome.

Authors:  T F Tsai; Y H Jiang; J Bressler; D Armstrong; A L Beaudet
Journal:  Hum Mol Genet       Date:  1999-08       Impact factor: 6.150

3.  The Prader-Willi phenotype of fragile X syndrome.

Authors:  Stephen T Nowicki; Flora Tassone; Michele Y Ono; Jessica Ferranti; Marie Francoise Croquette; Beth Goodlin-Jones; Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2007-04       Impact factor: 2.225

Review 4.  Metformin: repurposing opportunities for cognitive and mood dysfunction.

Authors:  Melissa A Ying; Nadia Maruschak; Rodrigo Mansur; Andre F Carvalho; Danielle S Cha; Roger S McIntyre
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

5.  Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome.

Authors:  Aaron L Carrel; Susan E Myers; Barbara Y Whitman; Jens Eickhoff; David B Allen
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

Review 6.  Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger.

Authors:  Marian S McDonagh; Shelley Selph; Alp Ozpinar; Carolyn Foley
Journal:  JAMA Pediatr       Date:  2014-02       Impact factor: 16.193

7.  Loss of Maged1 results in obesity, deficits of social interactions, impaired sexual behavior and severe alteration of mature oxytocin production in the hypothalamus.

Authors:  Carlos Dombret; Tuan Nguyen; Olivier Schakman; Jacques L Michaud; Hélène Hardin-Pouzet; Mathieu J M Bertrand; Olivier De Backer
Journal:  Hum Mol Genet       Date:  2012-08-02       Impact factor: 6.150

8.  Fragile x syndrome.

Authors:  Yingratana McLennan; Jonathan Polussa; Flora Tassone; Randi Hagerman
Journal:  Curr Genomics       Date:  2011-05       Impact factor: 2.236

Review 9.  Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome.

Authors:  Jennifer L Miller; Theresa V Strong; Janalee Heinemann
Journal:  Diseases       Date:  2015-06-03

10.  Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model.

Authors:  R E Monyak; D Emerson; B P Schoenfeld; X Zheng; D B Chambers; C Rosenfelt; S Langer; P Hinchey; C H Choi; T V McDonald; F V Bolduc; A Sehgal; S M J McBride; T A Jongens
Journal:  Mol Psychiatry       Date:  2016-04-19       Impact factor: 15.992

View more
  7 in total

1.  Metformin as targeted treatment in fragile X syndrome.

Authors:  A B C Dy; F Tassone; M Eldeeb; M J Salcedo-Arellano; N Tartaglia; R Hagerman
Journal:  Clin Genet       Date:  2017-09-25       Impact factor: 4.438

Review 2.  Fragile X syndrome and fragile X-associated disorders.

Authors:  Akash Rajaratnam; Jasdeep Shergill; Maria Salcedo-Arellano; Wilmar Saldarriaga; Xianlai Duan; Randi Hagerman
Journal:  F1000Res       Date:  2017-12-08

3.  Cyfip1 Haploinsufficiency Increases Compulsive-Like Behavior and Modulates Palatable Food Intake in Mice: Dependence on Cyfip2 Genetic Background, Parent-of Origin, and Sex.

Authors:  Richard K Babbs; Jacob A Beierle; Qiu T Ruan; Julia C Kelliher; Melanie M Chen; Ashley X Feng; Stacey L Kirkpatrick; Fabiola A Benitez; Fred A Rodriguez; Johanne J Pierre; Jeya Anandakumar; Vivek Kumar; Megan K Mulligan; Camron D Bryant
Journal:  G3 (Bethesda)       Date:  2019-09-04       Impact factor: 3.154

4.  Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases.

Authors:  Dragana Protic; Elber Y Aydin; Flora Tassone; Maria M Tan; Randi J Hagerman; Andrea Schneider
Journal:  Mol Genet Genomic Med       Date:  2019-05-18       Impact factor: 2.183

5.  Loss of Drosophila FMRP leads to alterations in energy metabolism and mitochondrial function.

Authors:  Eliana D Weisz; Atif Towheed; Rachel E Monyak; Meridith S Toth; Douglas C Wallace; Thomas A Jongens
Journal:  Hum Mol Genet       Date:  2018-01-01       Impact factor: 6.150

6.  Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.

Authors:  Kristin L Ayers; Benjamin S Glicksberg; Alastair S Garfield; Simonne Longerich; Joseph A White; Pengwei Yang; Lei Du; Thomas W Chittenden; Jeffery R Gulcher; Sophie Roy; Fred Fiedorek; Keith Gottesdiener; Sarah Cohen; Kari E North; Eric E Schadt; Shuyu D Li; Rong Chen; Lex H T Van der Ploeg
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

7.  Metformin treatment in young children with fragile X syndrome.

Authors:  Hazel Maridith B Biag; Laura A Potter; Victoria Wilkins; Sumra Afzal; Alexis Rosvall; Maria Jimena Salcedo-Arellano; Akash Rajaratnam; Ramiro Manzano-Nunez; Andrea Schneider; Flora Tassone; Susan M Rivera; Randi J Hagerman
Journal:  Mol Genet Genomic Med       Date:  2019-09-14       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.